Furthermore, only patients with overweight or obesity who received combination ICIs (i.e., anti-CTLA-4 + anti-PD-1) had a statistically significant improvement in PFS (p = 0.0044) and trended toward improved OS (p = 0.47). This evidence concerns the gene CTLA4 and Obesity.